1. Please check and comment entries here.
Table of Contents

    Topic review

    Brain-Epigenome of One-Carbon-Metabolism in ASD

    View times: 27
    Submitted by: Donato Gemmati

    Definition

    Autism spectrum disorder (ASD) is a complex neurodevelopmental condition affecting behavior and communication, presenting with extremely different clinical phenotypes and features. ASD etiology is composite and multifaceted with several causes and risk factors responsible for different individual disease pathophysiological processes and clinical phenotypes. From a genetic and epigenetic side, several candidate genes have been reported as potentially linked to ASD, which can be detected in about 10–25% of patients. Epigenome signature is a promising field in ASD clinical and translational research.

    1. Introduction

    Currently, autistic disorder, along with pervasive developmental disorder not otherwise specified (PDD–NOS), and Asperger syndrome represent the complex set of human neurodevelopmental diseases collectively known as autism spectrum disorder (ASD) [1]. ASD patients typically experience difficulty with social communication and interaction, restricted interests, and repetitive behaviors [2]. Indeed, despite the available technological advances and the innovative experimental approach of study, there is still not a definite and direct causal relationship or pattern to completely understand the pathogenesis of this complex disorder [3]. ASD has a strong heritable component making it essentially a genome-based human disease [4].

    In terms of ASD risk factors definition, there is unanimous agreement on the multifactorial framework of the etiology, suggesting that in most cases autism results from the interaction of multiple genetic and environmental factors, as often demonstrated for other complex diseases [5][6][7][8][9][10][11]. In this line, the role and interplay between genetics and environment with effects on epigenetics and epigenomics have become the subject of intensified researches [3][12][13].

    Among those genes associated with modification of disease susceptibility, the ones belonging to the folate homeostasis and methionine-homocysteine recycling are gaining interest in the context of different neuropsychiatric/neurobehavioral disorders [14][15]. In the past decades, several studies indicated that low folate levels and vitamin B12 together with high homocysteine (Hcy) levels were associated with neurodevelopmental disease, especially cognitive decline in psychogeriatric and psychiatric patients [16].

    2. One-Carbon Metabolism Pathway

    One-carbon metabolism is crucial in epigenetic regulation during embryo development and it is an integrated complex system composed of three main pathways: the folate cycle, the methionine cycle, and the transsulfuration pathway [17]. Overall, folate is crucial during neurodevelopment and it represents an efficient mediator of the crosstalk between genetics and epigenetics [18][19]. Deficiencies or unbalancing of the mutual levels of the different intracellular folate isoforms may negatively act during fetal growth and promote pediatric cancers, leukemia, neurodevelopmental disorders [20][21][22][23][24].

    Folate biochemistry has been deeply investigated in the past [25]. Briefly, once in the cells, folate is converted into its tetrahydrofolate (THF) active form by a two-step process dependent on NADPH and DHFR. As shown in Figure 1, 5,10-methylene-THF can be converted to 5-methyl-THF by the MTHFR enzyme and recycled back to THF by methionine synthase (MS). 5-methyl-THF may transfer its methyl group to cobalamin (B12) and the resulting methyl-cobalamin can act as a methyl-donor for Hcy to generate MS-mediated methionine.

    Genes 12 00782 g001 550

    Figure 1. Folate cycle and related genes. DHF: Dihydrofolate; THF: Tetrahydrofolate; SAM: S-adenosyl methionine; SAH: S-adenosyl Homocysteine; MTHFR: Methylenetetrahydrofolate reductase; RCF: Reduced folate carrier; DHFR: Dihydrofolate reductase; dUMP: Uridine monophosphate; dTMP: Thymidine monophosphate; DMG: Dimethylglycine; MS: Methionine synthase; CBS: Cystathionine-β-synthase; H-X: Methyl acceptor; H-CH3: Methylated acceptor; TS: Thymidylate synthase; MTHFD1: Methylenetetrahydrofolate dehydrogenase-1 (NADP+ dependent); CSE: Cystathionine γ-lyase; GCS: γ-glutamylcysteine synthetase; GSH: Glutathione; GSSG: Glutathione disulfide.

    Males typically show higher Hcy circulating levels compared to females (about 10–15% higher), though the sex gap is normally reduced by women menopause transition. Folate deficiency is associated with hyperhomocysteinemia, a recognized risk factor for several pathological conditions, with a strong inverse relation driven by the number of variant alleles in the MTHFR gene [25][22]. In a recent study performed in Israel where no national folic acid fortification programs exist, males, as expected, showed the lowest folate levels compared to females [26]. The consequence of low folate on Hcy levels was that males had higher Hcy than females also in presence of normal B12 levels and independently from age and estrogen effect [26].

    3. One-Carbon Metabolism in Autism and in Other Neurological Diseases: Brain Sex-Related Insights

    In many complex diseases, neurological conditions included, sex differences are associated with prevalence, course of the disease and outcome [27][28]. Among behavioral abnormalities, epidemiological studies consistently reported higher ASD prevalence in males compared with females (male: female ratio about 4:1), also considering the different role of abnormalities detected in the mother or father of ASD children [29][27][30][31]. Moreover, ASD females show a less severe disease phenotype highlighting sex differences also in a genetic view [32].

    Information and experimental data on sex differences between human brain developments according to the brain epigenome are very limited. Since some of such differences are evident in the brain before birth, they should happen during pregnancy in which sex imprinting actions can be mainly ascribed to the mother and less to the developing fetus. After birth, the genome, epigenome, and gender of the newborn take place, mutually interacting in determining the ultimate brain epigenome (Figure 2).

    Genes 12 00782 g002 550

    Figure 2. Brain epigenome imprinting. Schematic representation of genetics and epigenetics interactions occurring from conception to individual adult life. On the left, paternal and maternal hemigenome DNA demethylation processes occurring during fertilization (blue and pink lines respectively). In the middle, de novo global genome methylation at the blastocyst phase is shown as a dark dashed line. On the right, dashed red arrows indicate cross-interactions between different epigenetics factors (e.g., sex and gender).

    4. Conclusions and Future Perspectives in ASD

    Although the key role of folate isoforms balance/dysregulation in some complex pathological conditions has been demonstrated, more efforts and dedicated studies are needed to conclusively identify the most critical factors involved in ASD establishment. In particular, there is the mandatory need to elucidate the precise mechanisms by which sex-specific factors can modulate disease onset, severity and the different disease phenotypes at presentation, as well as how they can help and guide the choice of useful or unsafe dedicated treatments. To face these challenges, the synergy between advanced technologies and experimental/clinical investigations including pharmacogenetics/genomics/OMICS approaches [33][34][35][36] and personalized medicine [37] will allow a progression in the pathophysiological understanding of complex neurodevelopmental/neurological diseases. Earlier identification of informative molecular and biological biomarkers and an appropriate therapeutic choice are the unique effective strategy to follow (Figure 3). Accordingly, the sex gap in ASD prevalence reported to be about 4:1 (males-to-females respectively) appears to be more realistically close to 3:1 due to a potential diagnostic gender bias that does not efficiently include ASD girls, that are therefore at high risk of not receiving a proper and early diagnosis [38].

    Genes 12 00782 g003 550

    Figure 3. Folate OMICS-environment interactions on brain epigenomics. Snapshot of key risk factors for ASD development and key transgenerational pathophysiological features to be faced in a sex/gender approach.

    In conclusion, due to an unavoidable mutual influence between the psychological/social gender and the biological sex in human life, and that they both interact on the brain development by genetics and epigenetics actions, we cannot easily separate the effect of sex or gender on the brain epigenome establishment. Then we must begin to consider sex and gender combined together any time a difference appears in the clinical phenotype between women and men [39].

    The entry is from 10.3390/genes12050782

    References

    1. Bhat, S.; Acharya, U.R.; Adeli, H.; Bairy, G.M.; Adeli, A. Autism: Cause factors, early diagnosis and therapies. Rev. Neurosci. 2014, 25, 841–850.
    2. Available online: (accessed on 8 March 2021).
    3. Chaste, P.; Leboyer, M. Autism risk factors: Genes, environment, and gene-environment interactions. Dialogues Clin. Neurosci. 2012, 14, 281–292.
    4. Sandin, S.; Lichtenstein, P.; Kuja-Halkola, R.; Hultman, C.; Larsson, H.; Reichenberg, A. The Heritability of Autism Spectrum Disorder. JAMA 2017, 318, 1182–1184.
    5. Pivina, L.; Semenova, Y.; Dosa, M.D.; Dauletyarova, M.; Bjorklund, G. Iron Deficiency, Cognitive Functions, and Neurobehavioral Disorders in Children. J. Mol. Neurosci. 2019, 68, 1–10.
    6. Genovese, A.; Butler, M.G. Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD). Int. J. Mol. Sci. 2020, 21, 4726.
    7. Tisato, V.; Zuliani, G.; Vigliano, M.; Longo, G.; Franchini, E.; Secchiero, P.; Zauli, G.; Paraboschi, E.M.; Vikram Singh, A.; Serino, M.L.; et al. Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. PLoS ONE 2018, 13, e0193867.
    8. Gemmati, D.; Varani, K.; Bramanti, B.; Piva, R.; Bonaccorsi, G.; Trentini, A.; Manfrinato, M.C.; Tisato, V.; Care, A.; Bellini, T. “Bridging the Gap” Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era. Int. J. Mol. Sci. 2019, 21, 296.
    9. Tornese, G.; Iafusco, D.; Monasta, L.; Agnoletto, C.; Tisato, V.; Ventura, A.; Zauli, G.; Secchiero, P. The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. Acta Diabetol. 2014, 51, 239–246.
    10. Agostinis, C.; Bulla, R.; Tisato, V.; De Seta, F.; Alberico, S.; Secchiero, P.; Zauli, G. Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Hum. Reprod. 2012, 27, 2941–2947.
    11. Gemmati, D.; Occhionorelli, S.; Tisato, V.; Vigliano, M.; Longo, G.; Gonelli, A.; Sibilla, M.G.; Serino, M.L.; Zamboni, P. Inherited genetic predispositions in F13A1 and F13B genes predict abdominal adhesion formation: Identification of gender prognostic indicators. Sci. Rep. 2018, 8, 16916.
    12. Myers, S.M.; Voigt, R.G.; Colligan, R.C.; Weaver, A.L.; Storlie, C.B.; Stoeckel, R.E.; Port, J.D.; Katusic, S.K. Autism Spectrum Disorder: Incidence and Time Trends Over Two Decades in a Population-Based Birth Cohort. J. Autism Dev. Disord. 2019, 49, 1455–1474.
    13. Eshraghi, A.A.; Liu, G.; Kay, S.S.; Eshraghi, R.S.; Mittal, J.; Moshiree, B.; Mittal, R. Epigenetics and Autism Spectrum Disorder: Is There a Correlation? Front. Cell Neurosci. 2018, 12, 78.
    14. Shaik Mohammad, N.; Sai Shruti, P.; Bharathi, V.; Krishna Prasad, C.; Hussain, T.; Alrokayan, S.A.; Naik, U.; Radha Rama Devi, A. Clinical utility of folate pathway genetic polymorphisms in the diagnosis of autism spectrum disorders. Psychiatr. Genet. 2016, 26, 281–286.
    15. Long, S.; Goldblatt, J. MTHFR genetic testing: Controversy and clinical implications. Aust. Fam. Physician 2016, 45, 237–240.
    16. James, S.J. Autism and Folate-dependent One-carbon Metabolism: Serendipity and Critical Branch-point Decisions in Science. Glob. Adv. Health Med. 2013, 2, 48–51.
    17. Xu, J.; Sinclair, K.D. One-carbon metabolism and epigenetic regulation of embryo development. Reprod. Fertil. Dev. 2015, 27, 667–676.
    18. Desai, A.; Sequeira, J.M.; Quadros, E.V. The metabolic basis for developmental disorders due to defective folate transport. Biochimie 2016, 126, 31–42.
    19. Cai, S.; Quan, S.; Yang, G.; Ye, Q.; Chen, M.; Yu, H.; Wang, G.; Wang, Y.; Zeng, X.; Qiao, S. One Carbon Metabolism and Mammalian Pregnancy Outcomes. Mol. Nutr. Food Res. 2020, e2000734.
    20. Gemmati, D.; De Mattei, M.; Catozzi, L.; Della Porta, M.; Serino, M.L.; Ambrosio, C.; Cuneo, A.; Friso, S.; Krampera, M.; Orioli, E.; et al. DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: Is the risk reduction due to intracellular folate unbalancing? Am. J. Hematol. 2009, 84, 526–529.
    21. Gemmati, D.; Ongaro, A.; Scapoli, G.L.; Della Porta, M.; Tognazzo, S.; Serino, M.L.; Di Bona, E.; Rodeghiero, F.; Gilli, G.; Reverberi, R.; et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin’s lymphoma in adults. Cancer Epidemiol. Biomark. Prev. 2004, 13, 787–794.
    22. Gemmati, D.; Previati, M.; Serino, M.L.; Moratelli, S.; Guerra, S.; Capitani, S.; Forini, E.; Ballerini, G.; Scapoli, G.L. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 1761–1767.
    23. Ongaro, A.; De Mattei, M.; Della Porta, M.G.; Rigolin, G.; Ambrosio, C.; Di Raimondo, F.; Pellati, A.; Masieri, F.F.; Caruso, A.; Catozzi, L.; et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: Effects on methotrexate-related toxicity and survival. Haematologica 2009, 94, 1391–1398.
    24. Tisato, V.; Muggeo, P.; Lupiano, T.; Longo, G.; Serino, M.L.; Grassi, M.; Arcamone, E.; Secchiero, P.; Zauli, G.; Santoro, N.; et al. Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS). Genes 2019, 10, 634.
    25. Gemmati, D. Folate-Pathway Gene Variants in Cancer: Haematological Malignancies; Gemmati, D., Ed.; Transworld Research Network: Trivandrum, India, 2008; p. 269.
    26. Cohen, E.; Margalit, I.; Shochat, T.; Goldberg, E.; Krause, I. Sex Differences in Folate Levels: A Cross Sectional Study of a Large Cohort from Israel. Isr. Med. Assoc. J. 2021, 23, 17–22.
    27. May, T.; Adesina, I.; McGillivray, J.; Rinehart, N.J. Sex differences in neurodevelopmental disorders. Curr. Opin. Neurol. 2019, 32, 622–626.
    28. Piccini, P.; Montagnani, C.; de Martino, M. Gender disparity in pediatrics: A review of the current literature. Ital. J. Pediatr. 2018, 44, 1.
    29. Werling, D.M.; Geschwind, D.H. Sex differences in autism spectrum disorders. Curr. Opin. Neurol. 2013, 26, 146–153.
    30. Braunstein, V.L.; Peniston, N.; Perelman, A.; Cassano, M.C. The inclusion of fathers in investigations of autistic spectrum disorders. Res. Autism Spectr. Disord. 2013, 7, 8.
    31. Volkmar, F.R.; Szatmari, P.; Sparrow, S.S. Sex differences in pervasive developmental disorders. J. Autism Dev. Disord. 1993, 23, 579–591.
    32. Szatmari, P.; Liu, X.Q.; Goldberg, J.; Zwaigenbaum, L.; Paterson, A.D.; Woodbury-Smith, M.; Georgiades, S.; Duku, E.; Thompson, A. Sex differences in repetitive stereotyped behaviors in autism: Implications for genetic liability. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B, 5–12.
    33. Mitra, I.; Huang, B.; Mousavi, N.; Ma, N.; Lamkin, M.; Yanicky, R.; Shleizer-Burko, S.; Lohmueller, K.E.; Gymrek, M. Patterns of de novo tandem repeat mutations and their role in autism. Nature 2021, 589, 246–250.
    34. Searles Quick, V.B.; Wang, B.; State, M.W. Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders. Neuropsychopharmacology 2021, 46, 55–69.
    35. Kim, N.; Kim, K.H.; Lim, W.J.; Kim, J.; Kim, S.A.; Yoo, H.J. Whole Exome Sequencing Identifies Novel De Novo Variants Interacting with Six Gene Networks in Autism Spectrum Disorder. Genes 2020, 12, 1.
    36. Emberti Gialloreti, L.; Enea, R.; Di Micco, V.; Di Giovanni, D.; Curatolo, P. Clustering Analysis Supports the Detection of Biological Processes Related to Autism Spectrum Disorder. Genes 2020, 11, 1476.
    37. Mesleh, A.G.; Abdulla, S.A.; El-Agnaf, O. Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification. J. Pers. Med. 2021, 11, 41.
    38. Loomes, R.; Hull, L.; Mandy, W.P.L. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. J. Am. Acad. Child Adolesc. Psychiatry 2017, 56, 466–474.
    39. Cortes, L.R.; Cisternas, C.D.; Forger, N.G. Does Gender Leave an Epigenetic Imprint on the Brain? Front. Neurosci. 2019, 13, 173.
    More